Local News: Ashburn, VA 

 | 

Sign Up

 | 

Sign In

Gilead Sciences

Gilead Sciences News Editors

News Widget

Display the Gilead Sciences news headlines on your website.

Get the Topix Headlines Widget

Share & bookmark

RSS icon mobile icon

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

3 hrs ago | Information Technology

CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors

CytoDyn Inc. , a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, HIV/AIDS, Health

7 hrs ago | Customer Interaction Solutions

Gilead Sciences to Present at the Wells Fargo Securities 2013...

John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company at the conference on Tuesday, June 18 at 10:35 a.m. Eastern Time.

Comment?

Related Topix: Biotech, Gilead Sciences, Medicine, Healthcare Industry, Startups

7 hrs ago | Freshnews

Gilead Sciences to Present at the Wells Fargo Securities 2013...

Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

10 hrs ago | Insider Monkey

Gilead Sciences, Inc. (GILD), American International Group, Inc....

The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Insurance, American International Group, Construction, Berkshire Hathaway, Investment Services, Warren Buffett, Google

20 hrs ago | Customer Interaction Solutions

Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response ...

Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib , an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy.

Comment?

Related Topix: Biotech, Gilead Sciences, Medicine, Healthcare Industry, Startups

Fri Jun 14, 2013

PR-inside.com

New Market Research Report: Gilead Sciences, Inc. (GILD) - Financial...

It carries out the discovery, development and marketing of novel therapeutics for life threatening diseases.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Marketing, Infectious Diseases, Oncology, Sales

Seeking Alpha

Consider Biotech Gilead Sciences Because Of Atripla, Sofosbuvir And Great R&D

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Bristol Myers Squibb, HIV/AIDS, Health, Hepatitis

Thu Jun 13, 2013

HIV and Hepatitis

Gilead: Sofosbuvir for Hepatitis C Granted FDA Priority Review

Gilead's investigational nucleotide hepatitis C virus polymerase inhibitor sofosbuvir has been given priority review status by the U.S. Food and Drug Administration, with a target date in early December, the company announced last week.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Startups, Foster City, CA, CGI Pharmaceuticals

AmericanBankingNews.com

Gilead Sciences Rating Increased to Buy at Argus

Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a "buy" rating on shares of Gilead Sciences in a research note to investors on Friday, June 7th.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

Wed Jun 12, 2013

The Washington Post

Gilead's Viread Reduces HIV Risk for Drug Users by 49% in Study

Gilead Sciences Inc.'s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV's spread.

Comment?

Related Topix: HIV/AIDS, Health, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Centers for Disease Control and Prevention, Gay/Lesbian

Seeking Alpha

2 Services Sector Companies And 1 Biotech With Recent Intensive Insider Selling

There was intensive insider selling in EnerNOC in August 2010 when the stock was trading above $33 .

Comment?

Related Topix: Financial Markets, GAP, Retail, Apparel, Frank Sinatra, Jazz, TJX Companies, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Tue Jun 11, 2013

BioSpace

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Adds...

Dr. Glover was most recently President and Chief Executive Officer of YM BioSciences, an oncology drug development company acquired by Gilead Sciences for "Dr. Glover is a natural fit to round out our Board of Directors, adding a wealth of relevant strategic and operational knowledge," said , Ph.D., President and Chief Executive Officer of MEI ... (more)

Comment?

Related Topix: Oncology, Medicine, Biotech, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Hematology, Healthcare Law, Law

BioSpace

Gilead Sciences, Inc. to Present at the Goldman, Sachs & Co. 34th...

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Goldman Sachs 34th Annual Healthcare Conference in Rancho Palos Verdes, California.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Goldman Sachs, Financial Services, Investment Services, Startups, Rancho Palos Verdes, CA

Mon Jun 10, 2013

Drugs.com

Gilead Gets Priorty Review Designation for Sofobuvir

Jun. 7, 2013-- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Food and Drug Administration, Marketing

Seeking Alpha

A Full Pipeline At Alkermes

Despite the recent weakness in the overall market, the red-hot biotech sector has remained strong for the most part.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Alkermes, Amgen, Startups, Gilead Sciences, CGI Pharmaceuticals

Fri Jun 07, 2013

Freshnews

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Startups, CGI Pharmaceuticals, Marketing

Seeking Alpha

Gilead Sciences: Buy Stance For Investors

The US biotechnology industry, which is a speculative growth market, is going up as investors are becoming optimistic about its growth and investing big sums into biotech companies.

Comment?

Related Topix: Biotech, Gilead Sciences, Healthcare Industry, Science / Technology, Startups, CGI Pharmaceuticals, Financial Markets

Fri May 31, 2013

GuruFocus.com

Wedgewood Partners Trims High Gainers

As the CFA and CIO of Wedgewood Partners Inc., Guru David Rolfe has been managing Wedgewood's portfolio for over 18 years.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Charles Schwab, Investment Services

Business Journal

Biotech: Not easy, but worth it

Coming up on five years after the recession threatened to tear the heart out of the industry, biotech companies in the Bay Area continue to struggle in many ways.

Comment?

Related Topix: Genentech, Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Onyx Pharmaceuticals, BioMarin Pharmaceutical

Thu May 30, 2013

Insider Monkey

Hedge Funds Are Betting On Gilead Sciences, Inc.

GILD shareholders have witnessed an increase in hedge fund sentiment of late. There were 53 hedge funds in our database with GILD positions at the end of the previous quarter.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Financial Markets, Venture Capital, Emerging Technology

Ashburn Jobs